Therapeutic CD154 antibody for lupus: promise for the future?
AUTOR(ES)
Kelsoe, Garnett
FONTE
American Society for Clinical Investigation
RESUMO
Systemic lupus erythematosus (SLE) is a prototypical systemic autoimmune disease characterized by the production of pathogenic autoantibodies. A new study demonstrates that passive antibody specific for the TNF family member, CD154, ameliorates disease by reducing levels of self-reactive antibody in the serum. This study demonstrates a substantial potential for anti-CD154 antibody in the treatment of humoral autoimmunity.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=259140Documentos Relacionados
- The role of CD154 in organ transplant rejection and acceptance.
- Delineation of a Novel Pathway That Regulates CD154 (CD40 Ligand) Expression
- Delineation of a Novel Pathway That Regulates CD154 (CD40 Ligand) Expression
- CD28 and inducible costimulator (ICOS) signalling can sustain CD154 expression on activated T cells
- CD154 is a negative regulator of autoaggressive CD8+ T cells in type 1 diabetes